18.04.2012 • NewsAbbottsales and profitsPharmaceuticals

Abbott Lifts 2012 Forecast

Abbott Laboratories reported better-than-expected quarterly sales and earnings, fueled by strong demand for its Humira arthritis drug and its wide array of prescription medicines, nutritional products and medical devices.

The company earned $1.24 billion, or 78 cents per share, in the first quarter, up from $864 million, or 55 cents per share, in the year-earlier period.

Excluding special items, Abbott earned $1.03 per share. Analysts, on average, had forecast $1.00.

Revenue rose 4.6% to $9.46 billion, topping Wall Street expectations of $9.36 billion.

Global sales of Humira, by far the company's biggest product, surged 17% to $1.93 billion, putting it on track to leapfrog cholesterol fighter Lipitor and become the world's top-selling medicine.

Sales of nutritional products rose 10% to $1.6 billion, helped by new product launches and growing demand in emerging markets. The company's diagnostics products also reported solid growth.

Sales of vascular products, comprised largely of heart stents, fell 5% to $803 million on declining revenue from Boston Scientific's Promus stent. Promus is a private-label version of Abbott's widely used Xience stent; Abbott has shared in profits from Promus under a longstanding agreement to manufacture the product for Boston Scientific.

Abbott in October announced plans to spin off its branded prescription drug business into a separate publicly traded company amid criticism that it has become too dependent on Humira. The injected drug is facing growing competitive threats, including possible cheaper generic versions and a pill being developed by Pfizer, and concerns about its vulnerability have held back Abbott shares.

 

 

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.